|
|
Volumn 71, Issue 4, 2008, Pages 298-305
|
|
Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use
a
a
a
a
|
|
Author keywords
Caps; HIV 1 protease; HIV 2 protease; Protease inhibitors; Selectivity
|
|
Indexed keywords
AMPRENAVIR;
ATAZANAVIR;
DARUNAVIR;
INDINAVIR;
KNI 764;
LOPINAVIR;
NELFINAVIR;
PROTEINASE;
PROTEINASE INHIBITOR;
RITONAVIR;
SAQUINAVIR;
TIPRANAVIR;
TMC 126;
UNCLASSIFIED DRUG;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
AMINO ACID SEQUENCE;
ANTIVIRAL ACTIVITY;
ARTICLE;
BIOASSAY;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG POTENCY;
ENZYME INHIBITION;
ENZYME MECHANISM;
HUMAN IMMUNODEFICIENCY VIRUS 1;
HUMAN IMMUNODEFICIENCY VIRUS 2;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
INHIBITION KINETICS;
PHARMACOPHORE;
PRIORITY JOURNAL;
SEQUENCE HOMOLOGY;
STRUCTURE ACTIVITY RELATION;
VIRUS VIRULENCE;
HIV PROTEASE;
HIV PROTEASE INHIBITORS;
HYDROGEN BONDING;
KINETICS;
PYRIDINES;
PYRIMIDINONES;
PYRONES;
SAQUINAVIR;
STRUCTURE-ACTIVITY RELATIONSHIP;
SUBSTRATE SPECIFICITY;
SULFONAMIDES;
HUMAN IMMUNODEFICIENCY VIRUS 1;
HUMAN IMMUNODEFICIENCY VIRUS 2;
|
|
EID: 40449087448
PISSN: 17470277
EISSN: None
Source Type: Journal
DOI: 10.1111/j.1747-0285.2008.00647.x Document Type: Article |
|
Times cited : (94)
|
|
References (42)
|
